Trial Profile

A Retrospective Study to Evaluate the Efficacy and Safety of Lapatinib plus Capecitabine (LX) Compared with Lapatinib plus Trastuzumab and One Chemotherapy Drug (HLC) in Previously Treated HER2-Positive Metastatic Breast Cancer

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Lapatinib (Primary) ; Trastuzumab (Primary) ; Antineoplastics
Indications Advanced breast cancer
Focus Adverse reactions; Therapeutic Use

20 Jan 2020 New trial record
14 Dec 2019 Results presented at the 42nd Annual San Antonio Breast Cancer Symposium.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com